Vir Biotechnology has administered the first patient in one of three expansion cohorts of its Phase 1 trial for VIR‑5500, a prostate‑specific membrane antigen (PSMA)‑targeted, PRO‑XTEN® dual‑masked T‑cell engager designed for metastatic prostate cancer. The trial, registered as NCT05997615, is the first clinical exposure of VIR‑5500 and marks a critical step toward potential Phase 3 development.
The study evaluates VIR‑5500 monotherapy in late‑line metastatic castration‑resistant prostate cancer (mCRPC) and its combination with an androgen‑receptor pathway inhibitor in earlier‑line disease. The PRO‑XTEN platform masks the T‑cell engager until it reaches the tumor microenvironment, aiming to reduce systemic toxicity and enable outpatient administration—an advantage over existing T‑cell engagers that require inpatient monitoring.
This milestone validates the PRO‑XTEN technology and supports Vir’s strategy to deliver safer, outpatient‑compatible immunotherapies. By demonstrating tolerability in a real‑world patient, the company strengthens its case for a pivotal Phase 3 program slated for 2027, with Astellas Pharma taking over development after the Phase 1 phase.
The expansion cohort dosing follows a strong Q4 2025 earnings beat and the February 23 2026 collaboration with Astellas, which provided a $335 million upfront payment and shared development costs. The partnership extends Vir’s cash runway and positions the company to accelerate the clinical program, while the positive earnings results underscore robust financial health and investor confidence.
"The initiation of the VIR‑5500 expansion cohorts underscores the significant momentum behind this program and the enthusiasm we are seeing across the clinical community," said Marianne De Backer, CEO of Vir Biotechnology. "For patients with metastatic prostate cancer who have long faced limited treatment choices, VIR‑5500 may offer a renewed sense of hope and a potential path to better outcomes," added Dr. Johann de Bono, principal investigator of the study.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.